시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 겸상 적혈구증 치료 시장 보고서(2025년)
Sickle Cell Disease Treatment Global Market Report 2025
상품코드 : 1695003
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,240,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,019,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,799,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

겸상 적혈구증 치료 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 17.7%로 성장할 전망이며, 68억 달러로 성장이 예측됩니다. 예측 기간의 성장은 유전자 편집 및 유전자 치료, 신약 개발, 원격 의료 및 원격 모니터링, 세계 헬스 이니셔티브에 기인할 것으로 보입니다. 예측 기간 세계 동향에는 근치 요법, 대체 통증 관리, 세계 협력 관계, 환자 옹호 및 관여가 포함됩니다.

수혈 요구 증가는 당면한 겸상 적혈구증 치료 시장의 확대를 촉진할 것으로 예상됩니다. 수혈은 기증자에서 레시피엔트로의 혈액 또는 혈액 제제의 이송을 수반하는 의료 처치입니다. 수혈은 혈액의 산소 운반 능력을 높이고 혈관 폐색에 따른 합병증을 줄임으로써 검상 적혈구증(SCD) 환자 치료에 중요한 역할을 하고 있습니다. 예를 들어 2022년 12월 gov.UK에 따르면 영국에서는 2021년 헌혈이 증가하여 전국적으로 170만 건의 헌혈이 이루어졌습니다. 또한 2022년 1월 Mid-Atlantic Long-Term Care에 따르면 미국에서는 하루에 약 29,000단위의 적혈구, 5,000단위의 혈소판, 6,500단위의 혈장이 필요합니다. 따라서 수혈 수요 증가가 겸상 적혈구증 치료 시장 성장의 원동력이 되고 있습니다.

혈액 및 골수 이식 증가는 향후 수년간 겸상 적혈구증 치료 시장의 성장을 견인할 것으로 예상됩니다. 혈액 및 골수 이식은 겸상 적혈구증과 같은 질환을 치료하기 위해 건강하지 못한 조혈세포를 건강한 조혈세포와 대체하는 것을 포함합니다. 이 치료법에는 환자 자신의 몸에서 채취한 건강한 골수 세포를 주입하는 방법(자가이식) 및 기증자로부터 채취한 건강한 골수 세포를 주입하는 방법(동종이식)이 있습니다. 예를 들어 2024년 6월 국립이식기구(ONT)는 스페인이 2023년 골수 기증자 등록에 23,686명의 기증자를 추가해 2022년부터 8% 증가했다고 보고했습니다. 또, 동국에서는 조혈모세포 이식이 3,717건으로 사상 최고를 기록해, 인구 100만 명당 이식 건수는 77.4건이 되었습니다. 그 결과 혈액이식 및 골수이식 보급률이 상승하면서 겸상 적혈구증 치료 시장을 크게 끌어올릴 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Sickle cell disease (SCD), also referred to as sickle cell anemia, is a genetic disorder that impacts hemoglobin, a protein found in red blood cells. Individuals with sickle cell disease produce defective hemoglobin, known as hemoglobin S (HbS), due to a mutation in the hemoglobin gene. Treatment for sickle cell disease aims to alleviate blockages, improve blood flow, and repair damaged tissues.

The primary modalities for treating sickle cell disease include blood transfusion, pharmacotherapy, and bone marrow transplant. A blood transfusion involves the transfer of blood or blood products from a donor to a recipient. Sickle cell disease encompasses various types, such as sickle cell anemia, hemoglobin sickle C disease (HbSC), and others, with treatment administered through oral and parenteral routes. End users of these treatments include hospitals, specialty clinics, and other healthcare facilities.

The sickle cell disease treatment market research report is one of a series of new reports from The Business Research Company that provides sickle cell disease treatment market statistics, including sickle cell disease treatment industry global market size, regional shares, competitors with a sickle cell disease treatment market share, detailed sickle cell disease treatment market segments, market trends and opportunities and any further data you may need to thrive in the sickle cell disease treatment industry. This sickle cell disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sickle cell disease treatment market size has grown rapidly in recent years. It will grow from $2.95 billion in 2024 to $3.54 billion in 2025 at a compound annual growth rate (CAGR) of 19.7%. The growth in the historic period can be attributed to disease understanding, blood transfusions, pain management, hydroxyurea therapy.

The sickle cell disease treatment market size is expected to see rapid growth in the next few years. It will grow to $6.8 billion in 2029 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to gene editing and gene therapy, new drug development, telemedicine and remote monitoring, global health initiatives. Major trends in the forecast period include curative therapies, pain management alternatives, global collaborations, patient advocacy and engagement.

The growing need for blood transfusions is expected to propel the expansion of the sickle cell disease treatment market in the foreseeable future. Blood transfusion is a medical procedure involving the transfer of blood or blood products from a donor to a recipient. It plays a crucial role in the treatment of sickle cell disease (SCD) patients by enhancing the blood's oxygen-carrying capacity and reducing the complications associated with vaso-occlusion. For example, in December 2022, gov.UK reported that the UK witnessed an increase in blood donations in 2021, with 1.7 million donations made across the country. Moreover, in January 2022, according to Mid-Atlantic Long-Term Care, the United States requires approximately 29,000 units of red blood cells, 5,000 units of platelets, and 6,500 units of plasma daily. Therefore, the growing demand for blood transfusions is a driving force behind the growth of the sickle cell disease treatment market.

The increasing number of blood and bone marrow transplants is expected to drive the growth of the sickle cell disease treatment market in the coming years. A blood and bone marrow transplant involves replacing unhealthy blood-forming cells with healthy ones to treat conditions like sickle cell disease. This procedure can involve infusing healthy bone marrow cells either from the patient's own body (autologous transplant) or from a donor (allogeneic transplant). For example, in June 2024, the National Transplant Organization (ONT) reported that Spain added 23,686 donors to its Bone Marrow Donor Registry in 2023, an 8% increase from 2022. The country also achieved a record 3,717 hematopoietic stem cell transplants, translating to 77.4 transplants per million population. As a result, the rising prevalence of blood and bone marrow transplants is expected to significantly boost the sickle cell disease treatment market.

Leading companies in the sickle cell disease (SCD) treatment market are focusing on developing new oral suspension drugs to improve patient compliance, enhance drug efficacy, and provide more convenient treatment options, particularly for pediatric and elderly patients. Oral suspension drugs are liquid medications with solid particles suspended in a liquid, designed to make it easier for patients to swallow, especially children or those who have difficulty with pills. For example, in March 2024, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical manufacturing company, launched a room temperature-stable oral suspension of Hydroxyurea. This affordable SCD treatment is designed to increase accessibility in India, priced at less than 1% of imported alternatives. It offers precise dosing with oral syringes, providing a solution for patients of all ages without the need for cold storage.

In October 2022, Pfizer Inc., a pharmaceutical corporation headquartered in the United States, acquired Global Blood Therapeutics Inc. for $5.4 billion. This acquisition provides Pfizer with access to a premier sickle cell disease portfolio and pipeline, addressing the critical needs of an underserved patient population. Global Blood Therapeutics Inc. is a biopharmaceutical company based in the United States, specializing in the development and commercialization of therapies for individuals with sickle cell disease (SCD).

Major companies operating in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Silver Lake Research Corporation0.45, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Arena Pharmaceuticals Inc., Mast Therapeutics Inc.

North America was the largest region in the sickle cell disease treatment market in 2024. The regions covered in sickle cell disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sickle cell disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sickle cell disease treatment market consists of revenues earned by entities by providing services such as oxygen therapy, pulmonary hypertension management and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The sickle cell disease treatment market also includes sales of hydroxyurea, L-glutamine and voxlelotor. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sickle Cell Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sickle cell disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for sickle cell disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sickle cell disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Sickle Cell Disease Treatment Market Characteristics

3. Sickle Cell Disease Treatment Market Trends And Strategies

4. Sickle Cell Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Sickle Cell Disease Treatment Growth Analysis And Strategic Analysis Framework

6. Sickle Cell Disease Treatment Market Segmentation

7. Sickle Cell Disease Treatment Market Regional And Country Analysis

8. Asia-Pacific Sickle Cell Disease Treatment Market

9. China Sickle Cell Disease Treatment Market

10. India Sickle Cell Disease Treatment Market

11. Japan Sickle Cell Disease Treatment Market

12. Australia Sickle Cell Disease Treatment Market

13. Indonesia Sickle Cell Disease Treatment Market

14. South Korea Sickle Cell Disease Treatment Market

15. Western Europe Sickle Cell Disease Treatment Market

16. UK Sickle Cell Disease Treatment Market

17. Germany Sickle Cell Disease Treatment Market

18. France Sickle Cell Disease Treatment Market

19. Italy Sickle Cell Disease Treatment Market

20. Spain Sickle Cell Disease Treatment Market

21. Eastern Europe Sickle Cell Disease Treatment Market

22. Russia Sickle Cell Disease Treatment Market

23. North America Sickle Cell Disease Treatment Market

24. USA Sickle Cell Disease Treatment Market

25. Canada Sickle Cell Disease Treatment Market

26. South America Sickle Cell Disease Treatment Market

27. Brazil Sickle Cell Disease Treatment Market

28. Middle East Sickle Cell Disease Treatment Market

29. Africa Sickle Cell Disease Treatment Market

30. Sickle Cell Disease Treatment Market Competitive Landscape And Company Profiles

31. Sickle Cell Disease Treatment Market Other Major And Innovative Companies

32. Global Sickle Cell Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sickle Cell Disease Treatment Market

34. Recent Developments In The Sickle Cell Disease Treatment Market

35. Sickle Cell Disease Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기